CORCEPT THERAPEUTICS ($CORT) posted quarterly earnings results on Thursday, July 31st. The company reported earnings of $0.29 per share, beating estimates of $0.19 by $0.10. The company also reported revenue of $194,430,000, missing estimates of $203,382,645 by $-8,952,645.
You can see Quiver Quantitative's $CORT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CORCEPT THERAPEUTICS Insider Trading Activity
CORCEPT THERAPEUTICS insiders have traded $CORT stock on the open market 65 times in the past 6 months. Of those trades, 0 have been purchases and 65 have been sales.
Here’s a breakdown of recent trading of $CORT stock by insiders over the last 6 months:
- JOSEPH DOUGLAS LYON (See Remarks) has made 0 purchases and 13 sales selling 229,177 shares for an estimated $22,175,853.
- SEAN MADUCK (See Remarks) has made 0 purchases and 17 sales selling 204,993 shares for an estimated $17,464,920.
- JOSEPH K BELANOFF (Chief Executive Officer) has made 0 purchases and 15 sales selling 120,965 shares for an estimated $9,938,741.
- WILLIAM GUYER (Chief Development Officer) has made 0 purchases and 9 sales selling 84,979 shares for an estimated $5,991,025.
- DAVID L MAHONEY has made 0 purchases and 2 sales selling 27,352 shares for an estimated $2,030,452.
- DANIEL N JR SWISHER has made 0 purchases and 7 sales selling 13,200 shares for an estimated $892,424.
- GARY CHARLES ROBB (Chief Business Officer) has made 0 purchases and 2 sales selling 5,464 shares for an estimated $398,264.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CORCEPT THERAPEUTICS Hedge Fund Activity
We have seen 208 institutional investors add shares of CORCEPT THERAPEUTICS stock to their portfolio, and 207 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 988,917 shares (-6.3%) from their portfolio in Q1 2025, for an estimated $112,954,099
- TD ASSET MANAGEMENT INC added 819,882 shares (+inf%) to their portfolio in Q2 2025, for an estimated $60,179,338
- JUPITER ASSET MANAGEMENT LTD added 596,606 shares (+8176.0%) to their portfolio in Q1 2025, for an estimated $68,144,337
- INVESCO LTD. added 540,101 shares (+76.5%) to their portfolio in Q1 2025, for an estimated $61,690,336
- GAMMA INVESTING LLC removed 385,368 shares (-99.0%) from their portfolio in Q2 2025, for an estimated $28,286,011
- MAN GROUP PLC added 341,295 shares (+118.6%) to their portfolio in Q1 2025, for an estimated $38,982,714
- VOLORIDGE INVESTMENT MANAGEMENT, LLC removed 290,052 shares (-61.5%) from their portfolio in Q1 2025, for an estimated $33,129,739
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CORCEPT THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $CORT in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 05/06/2025
- Piper Sandler issued a "Overweight" rating on 04/03/2025
- Canaccord Genuity issued a "Buy" rating on 04/01/2025
- Truist Securities issued a "Buy" rating on 03/31/2025
To track analyst ratings and price targets for CORCEPT THERAPEUTICS, check out Quiver Quantitative's $CORT forecast page.
CORCEPT THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $CORT recently. We have seen 4 analysts offer price targets for $CORT in the last 6 months, with a median target of $143.5.
Here are some recent targets:
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $145.0 on 05/06/2025
- David Amsellem from Piper Sandler set a target price of $131.0 on 04/03/2025
- Edward Nash from Canaccord Genuity set a target price of $142.0 on 04/01/2025
- Joon Lee from Truist Securities set a target price of $150.0 on 03/31/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
